Trk receptor expression and inhibition in neuroblastomas

Clinical Cancer Research

Volumn 15, Issue 10, 2009, Pages 3244-3250

  Brodeur, Garrett M ^a,b   Minturn, Jane E ^a   Ho, Ruth ^a   Simpson, Anisha M ^a   Iyer, Radhika ^a   Varela, Carly R ^a   Light, Jennifer E ^a   Kolla, Venkatadri ^a   Evans, Audrey E ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BRAIN DERIVED NEUROTROPHIC FACTOR RECEPTOR; LESTAURTINIB; NERVE GROWTH FACTOR RECEPTOR; NEUROTROPHIN RECEPTOR; NEUROTROPHIN RECEPTOR P75; PHOSPHOTRANSFERASE INHIBITOR; PROTEIN TYROSINE KINASE A; TYROSINE KINASE RECEPTOR;

ANGIOGENESIS; AUTOCRINE EFFECT; BREAST CANCER; CANCER GROWTH; CANCER INHIBITION; CANCER RESISTANCE; CHILD; CLINICAL TRIAL; GENE AMPLIFICATION; GENE EXPRESSION; GENE REPRESSION; HUMAN; MICROENVIRONMENT; NERVE CELL DIFFERENTIATION; NEUROBLASTOMA; NONHUMAN; PANCREAS CANCER; PARACRINE SIGNALING; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN FUNCTION; RECEPTOR AFFINITY; RECEPTOR BLOCKING; REVIEW; RNA TRANSLATION; SIGNAL TRANSDUCTION; TISSUE DIFFERENTIATION;

ANIMALS; ENZYME INHIBITORS; HUMANS; MODELS, BIOLOGICAL; NEUROBLASTOMA; RECEPTOR, TRKA; RECEPTOR, TRKB; RECEPTOR, TRKC; SIGNAL TRANSDUCTION;

EID: 66149176909     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-08-1815     Document Type: Review

References (74)

1. Brodeur GM. Neuroblastoma: biological insights into a clinical enigma. Nat Rev Cancer 2003;3:203-216 PubMed doi:10.1038/nrc1014.
2. Kaplan DR, Hempstead BL, Martin-Zanca D, Chao MV, Parada LF. The trk proto-oncogene product: a signal transducing receptor for nerve growth factor. Science 1991;252:554-558 PubMed doi:10.1126/science.1850549. (Pubitemid 121000451)
3. Kaplan DR, Martin-Zanca D, Parada LF. Tyrosine phosphorylation and tyrosine kinase activity of the trk proto-oncogene product induced by NGF. Nature 1991;350:158-160 PubMed doi:10.1038/350158a0. (Pubitemid 21912187)
4. Klein R, Jing SQ, Nanduri V , O'Rourke E, Barbacid M. The trk proto-oncogene encodes a receptor for nerve growth factor. Cell 1991;65:189-97. PubMed doi:10.1016/0092-8674(91) 90419-Y. (Pubitemid 121001225)
5. Klein R, Nanduri V, Jing SA, et al. The trkB tyrosine protein kinase is a receptor for brain-derived neurotrophic factor and neurotrophin-3. Cell 1991;66:395-403. PubMed doi:10.1016/0092-8674(91)90628-C. (Pubitemid 121001357)
6. Lamballe F, Klein R, Barbacid M. trkC, a new member of the trk family of tyrosine protein kinases, is a receptor for neurotrophin-3. Cell 1991;66:967-79. PubMed doi:10.1016/0092-8674 (91)90442-90452 (Pubitemid 121001357)
7. Squinto SP, Stitt TN, Aldrich TH, et al. trkB encodes a functional receptor for brain-derived neurotrophic factor and neurotrophin-3 but not nerve growth factor. Cell 1991;65:885-93. PubMed doi:10.1016/0092-8674(91) 90395-F.
8. Chao MV, Bothwell MA, Ross AH, et al. Gene transfer and molecular cloning of the human NGF receptor. Science 1986;232:518-521 PubMed doi:10.1126/science. 3008331.
9. Hantzopoulos PA, Suri C, Glass DJ, Goldfarb MP, Yancopoulos GD. The low affinity NGF receptor, p75, can collaborate with each of the Trks to potentiate functional responses to the neurotrophins. Neuron 1994;13:187-201. PubMed doi:10.1016/0896-6273(94) 90469-90473
10. Klein R, Silos-Santiago I, Smeyne RJ, et al. Disruption of the neurotrophin-3 receptor gene trkC eliminates la muscle afferents and results in abnormal movements. Nature 1994;368:249-251 PubMed doi:10.1038/368249a0. (Pubitemid 24108842)
11. Klein R, Smeyne RJ, Wurst W, et al. Targeted disruption of the trkB neurotrophin receptor gene results in nervous system lesions and neonatal death. Cell 1993;75:113-122 PubMed. (Pubitemid 23306025)
12. Smeyne RJ, Klein R, Schnapp A, et al. Severe sensory and sympathetic neuropathies in mice carrying a disrupted Trk/NGF receptor gene [see comments]. Nature 1994;368:246-249 PubMed doi:10.1038/368246a0.
13. Barbacid M. Structural and functional properties of the TRK family of neurotrophin receptors. Ann N Y Acad Sci 1995;766:442-458 PubMed doi:10.1111/j.1749-6632.1995.tb26693.x.
14. Fagan AM, Zhang H, Landis S, Smeyne RJ, Silos-Santiago I, Barbacid M. TrkA, but not TrkC, receptors are essential for survival of sympathetic neurons in vivo. J Neurosci 1996;16:6208-6218 PubMed. (Pubitemid 26313995)
15. Levi-Montalcini R. The nerve growth factor 35 years later. Science 1987;237:1154-1162 PubMed doi:10.1126/science.3306916. (Pubitemid 17124912)
16. Pinon LG, Minichiello L, Klein R, Davies AM. Timing of neuronal death in trkA, trkB and trkC mutant embryos reveals developmental changes in sensory neuron dependence on Trk signalling. Development 1996;122:3255-3261 PubMed. (Pubitemid 26371989)
17. Dixon JE, McKinnon D. Expression of the trk gene family of neurotrophin receptors in prevertebral sympathetic ganglia. Brain Res Dev Brain Res 1994;77:177-82. PubMed doi:10.1016/0165-3806(94)90194-90195 (Pubitemid 124010780)
18. Schober A, Minichiello L, Keller M, et al. Reduced acetylcholinesterase (AChE) activity in adrenal medulla and loss of sympathetic preganglionic neurons in TrkA-deficient, but not TrkB-deficient, mice. J Neurosci 1997;17:891-903. PubMed. (Pubitemid 27043948)
19. Nakagawara A, Liu XG, Ikegaki N, et al. Cloning and chromosomal localization of the human TRK-B tyrosine kinase receptor gene (NTRK2). Genomics 1995;25:538-46. PubMed doi:10.1016/0888-7543(95)80055-Q.
20. O'Connell L, Hongo JA, Presta LG, Tsoulfas P. TrkA amino acids controlling specificity for nerve growth factor. J Biol Chem 2000;275:7870-7. PubMed doi:10.1074/jbc.275.11. 7870. (Pubitemid 30159694)
21. Urfer R, Tsoulfas P, O'Connell L, Hongo JA, Zhao W, Presta LG. High resolution mapping of the binding site of TrkA for nerve growth factor and TrkC for neurotrophin-3 on the second immunoglobulin- like domain of the Trk receptors. J Biol Chem 1998;273:5829-5840 PubMed doi:10.1074/jbc.273.10.5829. (Pubitemid 28124060)
22. Windisch JM, Marksteiner R, Lang ME, Auer B, Schneider R. Brain-derived neurotrophic factor, neurotrophin-3, and neurotrophin-4 bind to a single leucine-rich motif of TrkB. Biochemistry 1995;34:11256-11263 PubMed doi:10.1021/bi00035a035.
23. Cunningham ME, Stephens RM, Kaplan DR, Greene LA. Autophosphorylation of activation loop tyrosines regulates signaling by the TRK nerve growth factor receptor. J Biol Chem 1997;272:10957-10967 PubMed doi:10.1074/jbc.272.16.10957.
24. Segal RA, Bhattacharyya A, Rua LA, et al. Differential utilization of Trk autophosphorylation sites. J Biol Chem 1996;271:20175-20181 PubMed doi:10.1074/jbc.271.20.12103.
25. Kaplan DR, Miller FD. Signal transduction by the neurotrophin receptors. Curr Opin Cell Biol 1997;9:213-21. PubMed doi:10.1016/S0955-0674 (97)80065-80068
26. Qian X, Riccio A, Zhang Y, Ginty DD. Identification and characterization of novel substrates of Trk receptors in developing neurons. Neuron 1998;21:1017-29. PubMed doi:10.1016/S0896-6273(00)80620-80630 (Pubitemid 29018072)
27. Rui L, Herrington J, Carter-Su C. SH2-B is required for nerve growth factor-induced neuronal differentiation. J Biol Chem 1999;274:10590-10594 PubMed doi:10.1074/jbc.274.15.10590. (Pubitemid 129518359)
28. Greene LA, Kaplan DR. Early events in neurotrophin signalling via Trk and p75 receptors. Curr Opin Neurobiol 1995;5:579-87. PubMed doi:10.1016/0959- 4388(95)80062-X.
29. Barker PA, Lomen-Hoerth C, Gensch EM, Meakin SO, Glass DJ, Shooter EM. Tissue-specific alternative splicing generates two isoforms of the trkA receptor. J Biol Chem 1993;268:15150-15157 PubMed. (Pubitemid 23206668)
30. Clary DO, Reichardt LF. An alternatively spliced form of the nerve growth factor receptor TrkA confers an enhanced response to neurotrophin 3. Proc Natl Acad Sci U S A 1994;91:11133-11137 PubMed doi:10.1073/pnas.91.23.11133.
31. Tacconelli A, Farina AR, Cappabianca L, et al. TrkA alternative splicing: a regulated tumorpromoting switch in human neuroblastoma. Cancer Cell 2004;6:347-360 PubMed doi:10.1016/j.ccr.2004.09.011. (Pubitemid 39361436)
32. Allen SJ, Dawbarn D, Eckford SD, et al. Cloning of a non-catalytic form of human trkB and distribution of messenger RNA for trkB in human brain. Neuroscience 1994;60:825-34. PubMed doi:10.1016/0306-4522(94)90507-X. (Pubitemid 124016680)
33. Middlemas DS, Lindberg RA, Hunter T. trkB, a neural receptor protein-tyrosine kinase: evidence for a full-length and two truncated receptors. Mol Cell Biol 1991;11:143-153 PubMed.
34. Haapasalo A, Sipola I, Larsson K, et al. Regulation of TRKB surface expression by brain-derived neurotrophic factor and truncated TRKB isoforms. J Biol Chem 2002;277:43160-43167 PubMed doi:10.1074/jbc.M205202200. (Pubitemid 35285701)
35. Fryer RH, Kaplan DR, Kromer LF. Truncated trkB receptors on nonneuronal cells inhibit BDNF-induced neurite outgrowth in vitro. Exp Neurol 1997;148:616-627 PubMed doi:10.1006/exnr.1997.6699.
36. Menn B, Timsit S, Calothy G, Lamballe F. Differential expression of TrkC catalytic and noncatalytic isoforms suggests that they act independently or in association. J Comp Neurol 1998;401:47-64. PubMed doi:10.1002/(SICI)1096- 9861(19981109)401:1〈47::AIDCNE4〉3.0.CO;2-C. (Pubitemid 28485190)
37. Chao MV. Neurotrophin receptors: a window into neuronal differentiation. Neuron 1992;9:583-93. PubMed doi:10.1016/0896-6273(92) 90023-90027
38. Hempstead BL, Rabin SJ, Kaplan L, Reid S, Parada LF, Kaplan DR. Overexpression of the trk tyrosine kinase rapidly accelerates nerve growth factor-induced differentiation. Neuron 1992;9:883-96. PubMed doi:10.1016/0896-6273 (92)90241-90245
39. Chao MV, Hempstead BL. p75 and Trk: a two-receptor system. Trends Neurosci 1995;18:321-6. PubMed doi:10.1016/0166-2236(95)93922-K.
40. Bunone G, Mariotti A, Compagni A, Morandi E, Della Valle G. Induction of apoptosis by p75 neurotrophin receptor in human neuroblastoma cells. Oncogene 1997;14:1463-1470 PubMed doi:10.1038/sj.onc.1200972. (Pubitemid 27182436)
41. Rabizadeh S, Oh J, Zhong LT, et al. Induction of apoptosis by the low-affinity NGF receptor. Science 1993;261:345-348 PubMed doi:10.1126/science. 8332899. (Pubitemid 23281003)
42. Eggert A, Sieverts H, Ikegaki N, Brodeur GM. p75 mediated apoptosis in neuroblastoma cells is inhibited by expression of TrkA. Med Pediatr Oncol 2000;35:573-6. PubMed doi:10.1002/1096-911X(20001201)35:6〈573:: AIDMPO17〉 3.0.CO;2-A.
43. Nakagawara A, Arima M, Azar CG, Scavarda NJ, Brodeur GM. Inverse relationship between trk expression and N-myc amplification in human neuroblastomas. Cancer Res 1992;52:1364-1368 PubMed.
44. Nakagawara A, Arima-Nakagawara M, Scavarda NJ, Azar CG, Cantor AB, Brodeur GM. Association between high levels of expression of the TRK gene and favorable outcome in human neuroblastoma. N Engl J Med 1993;328:847-54. PubMed doi:10.1056/NEJM199303253281205. (Pubitemid 23084339)
45. Kogner P, Barbany G, Dominici C, Castello MA, Raschella G, Persson H. Coexpression of messenger RNA for TRK protooncogene and low affinity nerve growth factor receptor in neuroblastoma with favorable prognosis. Cancer Res 1993;53:2044-2050 PubMed. (Pubitemid 23145723)
46. Suzuki T, Bogenmann E, Shimada H, Stram D, Seeger RC. Lack of high-affinity nerve growth factor receptors in aggressive neuroblastomas. J Natl Cancer Inst 1993;85:377-384 PubMed doi:10.1093/jnci/85.5.377. (Pubitemid 23073155)
47. Nakagawara A, Brodeur GM. Role of neurotrophins and their receptors in human neuroblastomas: a primary culture study. Eur J Cancer 1997;33:2050-3. PubMed doi:10.1016/S0959-8049(97) 00280-283 (Pubitemid 28123452)
48. Scaruffi P, Cusano R, Dagnino M, Tonini GP. Detection of DNA polymorphisms and point mutations of high-affinity nerve growth factor receptor (TrkA) in human neuroblastoma. Int J Oncol 1999;14:935-938 PubMed.
49. Nakagawara A, Azar CG, Scavarda NJ, Brodeur GM. Expression and function of TRK-B and BDNF in human neuroblastomas. Mol Cell Biol 1994;14:759-767 PubMed. (Pubitemid 24013136)
50. Eggert A, Grotzer MA, Ikegaki N, Liu XG, Evans AE, Brodeur GM. Expression of the neurotrophin receptor TrkA down-regulates expression and function of angiogenic stimulators in SH-SY5Y neuroblastoma cells. Cancer Res 2002;62:1802-1808 PubMed. (Pubitemid 34408506)
51. Ho R, Eggert A, Hishiki T, et al. Resistance to chemotherapy mediated by TrkB in neuroblastomas. Cancer Res 2002;62:6462-6466 PubMed. (Pubitemid 35364107)
52. Matsumoto K, Wada RK, Yamashiro JM, Kaplan DR, Thiele CJ. Expression of brain-derived neurotrophic factor and p145TrkB affects survival, differentiation, and invasiveness of human neuroblastoma cells. Cancer Res 1995;55:1798-1806 PubMed.
53. Acheson A, Conover JC, Fandl JP, et al. A BDNF autocrine loop in adult sensory neurons prevents cell death. Nature 1995;374:450-453 PubMed doi:10.1038/374450a0.
54. Yamashiro DJ, Nakagawara A, Ikegaki N, Liu XG, Brodeur GM. Expression of TrkC in favorable human neuroblastomas. Oncogene 1996;12:37-41. PubMed. (Pubitemid 26041238)
55. Ryden M, Sehgal R, Dominici C, Schilling FH, Ibanez CF, Kogner P. Expression of mRNA for the neurotrophin receptor trkC in neuroblastomas with favourable tumour stage and good prognosis. Br J Cancer 1996;74:773-779 PubMed. (Pubitemid 26300770)
56. Pierotti MA, Vigneri P, Bongarzone I. Rearrangements of RET and NTRK1 tyrosine kinase receptors in papillary thyroid carcinomas. Recent Results Cancer Res 1998;154:237-247 PubMed.
57. Greco A, Miranda C, Pagliardini S, Fusetti L, Bongarzone I, Pierotti MA. Chromosome 1 rearrangements involving the genes TPR and NTRK1 produce structurally different thyroidspecific TRK oncogenes. Genes Chromosomes Cancer 1997;19:112-23. PubMed doi:10.1002/(SICI)1098-2264(199706)19:2〈112:: AIDGCC7〉 3.0.CO;2-1. (Pubitemid 27231486)
58. Rubin BP, Chen CJ, Morgan TW, et al. Congenital mesoblastic nephroma t(12;15) is associated with ETV6-3 gene fusion: cytogenetic and molecular relationship to congenital (infantile) fibrosarcoma. Am J Pathol 1998;153:1451-1458 PubMed.
59. Knezevich SR, McFadden DE, Tao W, Lim JF, Sorensen PH. A novel ETV6-3 gene fusion in congenital fibrosarcoma. Nat Genet 1998;18:184-187 PubMed doi:10.1038/ng0298-184.
60. Tognon C, Knezevich SR, Huntsman D, et al. Expression of the ETV6-3 gene fusion as a primary event in human secretory breast carcinoma. Cancer Cell 2002;2:367-76. PubMed doi:10.1016/S1535-6108(02)00180-190 (Pubitemid 41039103)
61. Liu Q, Schwaller J, Kutok J, et al. Signal transduction and transforming properties of the TELTRKC fusions associated with t(12;15)(p13;q25) in congenital fibrosarcoma and acute myelogenous leukemia. EMBO J 2000;19:1827-1838. PubMed doi:10.1093/emboj/19.8.1827.
62. Eguchi M, Eguchi-Ishimae M, Tojo A, et al. Fusion of ETV6 to neurotrophin-3 receptor TRKC in acute myeloid leukemia with t(12;15)(p13;q25). Blood 1999;93:1355-1363 PubMed.
63. Eggert A, Grotzer MA, Ikegaki N, et al. Expression of the neurotrophin receptor TrkB is associated with unfavorable outcome in Wilms' tumor. J Clin Oncol 2001;19:689-696 PubMed. (Pubitemid 32119082)
64. Rutkowski S, von Bueren A, von Hoff K, et al. Prognostic relevance of clinical and biological risk factors in childhood medulloblastoma: results of patients treated in the prospective multicenter trial HIT'91Clin Cancer Res 2007;13:2651-7. PubMed doi:10.1158/1078-0432.CCR-06-1779.
65. McGregor LM, McCune BK, Graff JR, et al. Roles of trk family neurotrophin receptors in medullary thyroid carcinoma development and progression. Proc Natl Acad Sci U S A 1999;96:4540-4545 PubMed doi:10.1073/pnas.96.8.4540.
66. George DJ, Suzuki H, Bova GS, Isaacs JT. Mutational analysis of the TrkA gene in prostate cancer. Prostate 1998;36:172-80. PubMed doi:10.1002/(SICI)1097- 0045(19980801)36:3〈172:: AID-PROS5〉3.0.CO;2-J. (Pubitemid 28341129)
67. Pflug BR, Dionne C, Kaplan DR, Lynch J, Djakiew D. Expression of a Trk high affinity nerve growth factor receptor in the human prostate. Endocrinology 1995;136:262-268 PubMed doi:10.1210/en.136.1.262.
68. Dolle L, El Yazidi-Belkoura I, Adriaenssens E, Nurcombe V, Hondermarck H. Nerve growth factor overexpression and autocrine loop in breast cancer cells. Oncogene 2003;22:5592-5601 PubMed doi:10.1038/sj.onc.1206805. (Pubitemid 37102695)
69. Descamps S, Pawlowski V, Revillion F, et al. Expression of nerve growth factor receptors and their prognostic value in human breast cancer. Cancer Res 2001;61:4337-4340 PubMed. (Pubitemid 32685755)
70. Evans AE, Kisselbach KD, Liu X, et al. Effect of CEP-751 (KT-6587) on neuroblastoma xenografts expressing TrkB. Med Pediatr Oncol 2001;36:181-4. PubMed doi:10.1002/1096-911X(20010101)36: 1〈181::AID-MPO1043〉3.0.CO;2- Q.
71. Evans AE, Kisselbach KD, Yamashiro DJ, et al. Antitumor activity of CEP-751 (KT-6587) on human neuroblastoma and medulloblastoma xenografts. Clin Cancer Res 1999;5:3594-3602 PubMed.
72. Chan E, Mulkerin D, Rothenberg M, et al. A phase I trial of CEP-701 + gemcitabine in patients with advanced adenocarcinoma of the pancreas. Invest New Drugs 2008;26:241-7. PubMed doi:10.1007/s10637-008-9118-9123
73. Marshall JL, Kindler H, Deeken J, et al. Phase I trial of orally administered CEP-701, a novel neurotrophin receptor-linked tyrosine kinase inhibitor. Invest New Drugs 2005;23:31-37 PubMed doi:10.1023/B:DRUG.000- 0047103.64335.b0. (Pubitemid 39505949)
74. Undevia SD, Vogelzang NJ, Mauer AM, Janisch L, Mani S, Ratain MJ. Phase I clinical trial of CEP-2563 dihydrochloride, a receptor tyrosine kinase inhibitor, in patients with refractory solid tumors. Invest New Drugs 2004;22:449-458 PubMed doi:10.1023/B:DRUG.0000036687.26604.8c. (Pubitemid 39619821)